Longeveron Inc. heads into its May 13 earnings event with short sellers unwinding a crowded position — yet the borrow market remains expensive enough to keep the setup tense.
Short interest peaked ferociously in mid-April, then began a rapid retreat. SI as a percentage of the free float hit 14.3% on April 10 — more than double the 5% level it had held at the start of April — before rolling back sharply to 7.9% by May 7. The one-month change still shows a net 30% increase in shares short, meaning the April build left a residual footprint even after the unwind. With the stock down 27% over the past month to $0.85, bears were pressing a falling knife; now some are pocketing gains as the print approaches.
The borrow market tells a story of gradually easing pressure, but not outright relief. Cost to borrow peaked above 140% annualised in late March, then collapsed to a range of roughly 49–50% where it has plateaued for the past week. That is still aggressive for a $0.85 stock — lending desks are charging almost half the stock's value per year to hold the short. Availability has tightened meaningfully from the 52-week maximum; the lending pool currently has about 30% of already-borrowed shares available for new borrows, placing it in the tight-to-very-tight zone. The overall borrow setup has loosened from its extreme, but remains a meaningful friction cost for anyone building new shorts from scratch.
The one firm still formally covering LGVN, HC Wainwright, trimmed its price target to $8.00 from $10.00 this week while keeping a Buy rating — a notable downward revision but still implying roughly 850% upside from the current price. That gap between the street target and the trading price is almost entirely a function of how far the stock has fallen; the mean target across two covering analysts sits at $6.82. Bulls point to the ELPIS II study of Lomecel-B in Hypoplastic Left Heart Syndrome, where a prior interim showed 100% five-year transplant-free survival against an 80% historical baseline. Bears counter that the stock has shed more than half its value year-to-date, with unexpected safety signals surfacing in clinical development and no clear funding runway. ORTEX's short score has eased from 74.8 to 73.1 over the past two weeks — still elevated, ranking in roughly the 8th percentile of all stocks, meaning very few names carry a heavier short-side signal.
Insider activity from May 1 is worth noting, even if the context is limited. The CEO, CFO, CTO, CMO, and General Counsel all received share awards on the same date — 500,000 shares for the CEO and 250,000 each for the others — at zero cost, making these compensation grants rather than open-market purchases. Small offsetting sells from April 1 (the CEO sold roughly 4,700 shares at $1.12, the CFO around 13,100) appear to be tax-withholding disposals. There is no evidence of meaningful open-market buying by insiders at current prices, which is one angle the bull case would benefit from.
The last confirmed earnings event on record — a March 17 release — produced a one-day move of +10%, though the five-day move faded to near flat. The May 13 date sits five days away, making it the most immediate catalyst on the calendar. With SI still at nearly 8% of the float, borrow costs running near 50%, and the HC Wainwright target cut fresh this week, the question going into that print is how much of the recent short unwind reflects genuine conviction change versus pre-announcement risk reduction.
See the live data behind this article on ORTEX.
Open LGVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
